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We read with interest the paper in CMI by Hsueh
et al. [1] concerning increasing resistance tomacro-
lides in Streptococcus pneumoniae despite a > 50%
decrease inmacrolide consumption.Wewould like
to stress the importance of possible clinical thera-
peutic failures caused by macrolide-resistant
S. pneumoniae in patients treated with distantly
related compounds such as pristinamycin.
Pristinamycin has been used widely in France
for nearly 50 years in the treatment of staphylo-
coccal and streptococcal infections, including
those caused by S. pneumoniae and strains resist-
ant to macrolides or related compounds [2,3].
Since our report of the ﬁrst macrolide-resistant
S. pneumoniae in France [4], > 50% of all French
S. pneumoniae isolates have become resistant to
macrolides, which is the highest reported preval-
ence in the western world, although lower than
that in south-east Asia. About 97% of these
isolates are of the macrolides, lincosamides,
streptogramins (MLSB) phenotype (E. Varron,
personal communication). Despite this high pre-
valence, > 99% of the macrolide-resistant isolates
remain fully susceptible to pristinamycin, with a
mode MIC of 0.25–0.5 mg ⁄L (25th Reunion Inter-
disciplinaire de Chimothe´rapie Anti-Infectieuse,
Paris 2005, abstract 346 ⁄ 63p).
Pristinamycin is amixture of two compounds, A
(Pri II) and B (Pri I), which are produced naturally
by Streptomyces pristinaespiralis. Each compound is
bacteriostatic, but their association is synergic and
bactericidal. Despite resistance to compound B in
MLSB-resistant streptococci, the synergic activity is
not abolished, and this prevents the emergence
of resistance to the combination. Quinupristin ⁄
dalfopristin, a semisynthetic derivative, has very
similar activity [6]. However, diminished killing of
these strains bypristinamycinhas beenobserved in
some studies [7,8], and we have observed the
occurrence of a breakthrough case of meningitis
caused by a macrolide-resistant S. pneumoniae in a
patient treated with pristinamycin.
A woman aged 55 years was hospitalised on 31
October 2005 with a clinical diagnosis of pneu-
monia. Upon examination, she had clear signs of
meningitis,with cephalea, vomiting, neck stiffness,
a vast array of neurological disorders, and a
temperature of 39.5C. During the previous
10 days, she had been treated with pristinamycin
2 · 1 gdaily for an acute bronchitis. She had 10 600
white blood cells ⁄mm3 with 92% neutrophils, and
a C-reactive protein level of 113 mg ⁄L. The cere-
brospinal ﬂuid contained 674 cells ⁄mm3 with 95%
neutrophils, and numerous S. pneumoniae cells
were observed following Gram’s stain. Two blood
cultures were found to be positive in < 24 h. The
isolates from the spinal ﬂuid and blood were
identical, with low-level resistance to b-lactams
(MICs: penicillin G 0.75 mg ⁄L; amoxycillin and
cefotaxime 0.5 mg ⁄L), resistance to tetracyclines,
co-trimoxazole, macrolides and related com-
pounds. The MIC of pristinamycin was 0.25 mg ⁄L,
with a minimum bactericidal concentration (MBC)
of 2 mg ⁄L. The strain belonged to serotype 19 A,
which has emerged during recent years as being
responsible for serious pneumococcal infections,
including cases of meningitis (E. Varon, personal
communication). The patient was treated with
ceftriaxone 6 g ⁄day and vancomycin 6 g ⁄day for
only 5 days because of acute renal failure. She also
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received 40 mg dexamethasone over the course of
4 days. By day 20 the patient had recovered.
Conﬂicting results concerning the clinical efﬁc-
acy of pristinamycin against macrolide-resistant
S. pneumoniae with the MLSB phenotype have
been reported [1,9,10]. In a double-blind study
comparing the efﬁcacy of pristinamycin with
amoxycillin for the treatment of community-
acquired pneumonia, pristinamycin was signiﬁ-
cantly less effective than amoxycillin (63.6% vs.
86.6%) in bacteraemic patients, with a 50% failure
rate for macrolide-resistant S. pneumoniae [2].
Taken together, these data emphasise the need
to reconsider the choice of pristinamycin or
quinupristin ⁄dalfopristin for the treatment of
macrolide-resistant pneumococcal infections.
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First community-acquired methicillin-
resistant Staphylococcus aureus (MRSA)
strains in Croatia
10.1111/j.1469-0691.2006.01493.x
The recent article in CMI by Kluytmans-Vanden-
Bergh and Kluytmans [1] described the current
situation concerning community-acquired methi-
cillin-resistant Staphylococcus aureus (CA-MRSA)
infections. CA-MRSA is becoming an increasing
public health problem worldwide, and it was
concluded that reported prevalence rates of CA-
MRSA probably vary among countries because of
the different deﬁnitions used to distinguish
between CA-MRSA and hospital-acquired MRSA
(HA-MRSA), and because of the different settings
in which the studies have been undertaken. We
would like to report the ﬁrst infections in the
community attributable to MRSA that have been
observed at the University Hospital for Infectious
Diseases in Zagreb, Croatia.
Four S. aureus isolates were recovered from
skin and soft-tissue infections and nasal swabs
from two outpatients and one inpatient hospital-
ised in the Trauma Hospital in Zagreb. These
isolates had a low level of resistance to oxacillin,
penicillin, tetracyclines and kanamycin, and were
susceptible to other anti-staphylococcal antimi-
crobial agents tested. Two pulsed-ﬁeld gel elec-
trophoresis (PFGE) types, designated A and G,
were identiﬁed, and these were identical to the
Polish MRSA clones, HeMRSA-Pol4 (PFGE type
A) and HeMRSA-Pol2 (PFGE type G), described
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